Holen Sie sich die Stockscreener-App
0.00
100.00%
-8.16
Schlusskurs vom Vortag:
$8.16
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$564.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.04M
KGV:
0.00
EPS:
-1.58
Netto-Cashflow:
$-27.38M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$8.345
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Firmenname
Regulus Therapeutics Inc
Sektor
Branche
Telefon
858-202-6300
Adresse
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Vergleichen Sie RGLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
0.00 | 564.26M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.73 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.48 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.90 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.00 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.37 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-08-02 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-18 | Eingeleitet | Leerink Partners | Outperform |
| 2018-03-28 | Eingeleitet | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | Eingeleitet | Leerink Partners | Outperform |
| 2017-06-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-03-06 | Bestätigt | Wedbush | Outperform |
| 2017-01-30 | Herabstufung | Needham | Buy → Hold |
| 2017-01-30 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-11-02 | Bestätigt | Needham | Buy |
| 2016-07-25 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | FBR Capital | Outperform |
| 2016-06-28 | Bestätigt | Needham | Buy |
| 2016-06-07 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-04-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-09 | Eingeleitet | Guggenheim | Buy |
| 2015-04-21 | Fortgesetzt | FBR Capital | Outperform |
| 2014-11-24 | Eingeleitet | Deutsche Bank | Buy |
| 2014-08-07 | Bestätigt | FBR Capital | Outperform |
| 2013-08-14 | Bestätigt | Needham | Buy |
Alle ansehen
Regulus Therapeutics Inc Aktie (RGLS) Neueste Nachrichten
Is Regulus Therapeutics Inc. a good long term investmentFree Daily Trading Room Entry - Jammu Links News
What analysts say about Regulus Therapeutics Inc. stockTremendous financial leverage - Jammu Links News
Will Regulus Therapeutics Inc. stock split in the near futureHigh Potential Shares - Newser
Why Regulus Therapeutics Inc. stock attracts strong analyst attentionFree Consultation - Newser
How Regulus Therapeutics Inc. stock performs during market volatilityAlpha Stock Ideas - Newser
What makes Regulus Therapeutics Inc. stock price move sharplyHigh Reward Swing Trades - Newser
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of “Hold” from Analysts - Defense World
Oppenheimer & Co. Inc. Takes Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics to be Acquired by Novartis - TipRanks
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Seeking Alpha
Regulus Investor Drops Suit After $1.7 Billion Novartis Sale - Bloomberg Law News
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion - Yahoo Finance
Novartis concludes acquisition of Regulus Therapeutics - Medical Dialogues
Novartis Completes Tender Offer for Regulus Therapeutics - PharmiWeb.com
Novartis (NVS) Concludes Acquisition Offer for Regulus Therapeutics | NVS Stock News - GuruFocus
Novartis completes acquisition of Regulus Therapeutics - MarketScreener
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer - The Manila Times
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $8.50 Consensus Price Target from Analysts - Defense World
Biopharma Deal Premiums Paint Picture of Cutthroat Negotiations - BioSpace
Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulu - GuruFocus
Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS) - GuruFocus
Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout (NASDAQ:RGLS) - Seeking Alpha
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis - GlobeNewswire Inc.
Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows - Fierce Pharma
Novartis arm commences tender offer to buy Regulus Therapeutics - Medical Dialogues
Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined - Endpoints News
Novartis announces commencement of tender offer to acquire Regulus Therapeutics - The Manila Times
Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics - marketscreener.com
Novartis Launches Tender Offer for Regulus Therapeutics Takeover - MarketScreener
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Seeking Alpha
With IPO markets dead, biotechs search for M&A - Axios
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView
Latham and Covington Advise on Novartis’s Acquisition of Regulus - Law Street Media
Unlocking Profits with the Magical Signal How the Bullish Signal Transformed Regulus Therapeutics - AInvest
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - The Globe and Mail
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World
Novartis to Acquire Regulus Therapeutics - San Diego Business Journal
Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com - Defense World
Regulus Therapeutics’ Q1 2025 Results Signal a New Era for Kidney Disease Treatment and Investor Value - AInvest
Regulus: Q1 Earnings Snapshot - Norwalk Hour
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - StreetInsider
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway - GuruFocus
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway | RGLS Stock News - GuruFocus
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Renaissance Technologies LLC - Defense World
Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com
What is Leerink Partnrs’ Estimate for RGLS Q1 Earnings? - Defense World
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire
Regulus Therapeutics' $1.7 Billion Deal with Novartis Faces Scrutiny: Is the Price Fair? - AInvest
Finanzdaten der Regulus Therapeutics Inc-Aktie (RGLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):